Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

5-HT(3) receptor antagonists.

Higgins1, Kilpatrick

  • 1PRPN CNS, F. Hoffmann-La Roche, 4070 Basel, Switzerland. guy_a.higgins@roche.com

Expert Opinion on Investigational Drugs
|January 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mr. Higgins' Case of Traumatic Tetanus.

Medical examiner (Philadelphia, Pa.)·2023
Same author

A Meteorological Table.

The Medical and physical journal·2018
Same author

A Meteorological Table.

The Medical and physical journal·2018
Same author

A Meteorological Table.

The Medical and physical journal·2018
Same author

SPECIAL DISCUSSION ON ENDOCRINE THERAPY.

Proceedings of the Royal Society of Medicine·2009
Same author

Poor uptake of reproductive health screening services by female renal transplant recipients.

Irish medical journal·2006
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Selective 5-HT(3) receptor antagonists show promise for treating nausea and irritable bowel syndrome. However, their potential for central nervous system (CNS) diseases like anxiety and Alzheimer's remains largely unfulfilled, with no approved CNS applications yet.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • The 5-HT(3) receptor is a crucial ligand-gated ion channel found throughout the nervous system.
  • Selective 5-HT(3) receptor antagonists have been developed, with early animal studies indicating broad therapeutic potential.

Purpose of the Study:

  • To review the therapeutic applications and development of selective 5-HT(3) receptor antagonists.
  • To assess the progress and challenges in utilizing these antagonists for central nervous system (CNS) disorders.

Main Methods:

  • Literature review of preclinical and clinical studies on 5-HT(3) receptor antagonists.
  • Analysis of drug development pipelines and regulatory approvals.

Main Results:

  • Selective 5-HT(3) receptor antagonists are successfully marketed as anti-emetics and for irritable bowel syndrome.

Related Experiment Videos

  • Despite promising animal data for CNS conditions like anxiety, schizophrenia, and Alzheimer's disease, no selective 5-HT(3) receptor antagonist has gained approval for any CNS indication.

    • Conclusions:

    • The therapeutic utility of 5-HT(3) receptor antagonists has been validated in peripheral applications (emesis, IBS).
    • Significant hurdles remain in translating the potential of these antagonists to effective treatments for CNS diseases.